Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART-DISEASE INMIDDLE-AGED PATIENTS - A 14-MONTH PILOT-STUDY
Autore:
BATISTA J; STUSSER R; SAEZ F; PEREZ B;
Indirizzi:
UNIV HAVANA,CLIN RES CTR,34 ST 4501E-47Y 45 HAVANA 13 CUBA UNIV HAVANA,CARDIOVASC LAB HAVANA 13 CUBA
Titolo Testata:
International journal of clinical pharmacology and therapeutics
fascicolo: 3, volume: 34, anno: 1996,
pagine: 134 - 137
SICI:
0946-1965(1996)34:3<134:EOPOHA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
LIPOPROTEINS;
Keywords:
LIPID-LOWERING-DRUG; CORONARY HEART DISEASE; PRIMARY HYPERLIPIDEMIA; POLICOSANOL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
J. Batista et al., "EFFECT OF POLICOSANOL ON HYPERLIPIDEMIA AND CORONARY HEART-DISEASE INMIDDLE-AGED PATIENTS - A 14-MONTH PILOT-STUDY", International journal of clinical pharmacology and therapeutics, 34(3), 1996, pp. 134-137

Abstract

To find out the long-term lipid-lowering efficacy of policosanol in low dose and its influence in the evolution of coronary heart disease (CHD), a pilot clinical randomized single-blind, placebo-controlled trial was conducted on 23 middle-aged outpatients, with well documented diagnosis of chronic CHD and primary or marginal hyperlipidemia. Twelvepatients received policosanol tablets of 1 mg twice daily, and 11 patients placebo in the same fashion, followed with rest and stress electrocardiogram (EGG), and serum lipid blood samples by 14 months. The treated group showed significant reduction of total cholesterol in 14.8%(p less than or equal to 0.001) and of low density lipoprotein (LDL) in 15.6% (p less than or equal to 0.05), against non significant increase of 3% and 5.5%, respectively, in the placebo group. No patient hadnew coronary events in both groups, but 5 of 12 treated patients exhibited a clinical tendency to improve their CHD, in comparison with no one in the placebo group (p less than or equal to 0.05). These findings show the effectiveness of low dose of policosanol lowering total cholesterol and LDL levels and suggest a CHD improvement in middle-aged patients with primary or marginal hyperlipidemia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 03:12:21